Wealth Enhancement Advisory Services’s Aldeyra Therapeutics ALDX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.4K	Sell	47,518 -13,569	-22%	-$23.3K	﹤0.01%	3796
2026 Q1	$101K	Buy	61,087 +28,404	+87%	+$124K	﹤0.01%	3319
2025 Q4	$133K	Sell	32,683 -159	-0.5%	-$817	﹤0.01%	3374
2025 Q3	$184K	Buy	32,842 +5,556	+20%	+$29K	﹤0.01%	3168
2025 Q2	$117K	Buy	27,286 +16,376	+150%	+$42.3K	﹤0.01%	3113
2025 Q1	$62.7K	Buy	+10,910	New	+$64.5K	﹤0.01%	2834

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Wealth Enhancement Advisory Services's ALDX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Aldeyra Therapeutics (ALDX) stake by 22% in Q2 2026, selling an estimated $23.3K and leaving 47,518 shares worth $98.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3796.

Wealth Enhancement Advisory Services first reported a position in ALDX in Q1 2025 and has held it in 6 quarters since. The position peaked at $184K in Q3 2025. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Wealth Enhancement Advisory Services held 47,518 shares of Aldeyra Therapeutics worth $98.4K as of Q2 2026.
Wealth Enhancement Advisory Services sold 13,569 Aldeyra Therapeutics shares in Q2 2026, an estimated $23.3K.
Aldeyra Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3796 holding.
Wealth Enhancement Advisory Services first reported a position in Aldeyra Therapeutics in Q1 2025 and has held it in 6 quarters since.
Wealth Enhancement Advisory Services's Aldeyra Therapeutics position peaked at $184K in Q3 2025.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.